UNSPSC 51262102: Silodosin

This classification denotes an alpha-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CUZ39LUY82. European Medicines Agency schedules Silodosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23152. Silodosin generally arises in the molecular formula C25H32F3N3O4. The term SILODOSIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16., no. 1.2002, list 47.) Most nations schedule silodosin under HS 29339990 and SITC 51577.

As of Q4 2014, SILODOSIN remains the US FDA Preferred Term for this commodity. Silodosin bears US NLM identifiers UMLS ID C1870115 and NCI Concept Code C81372. SMILES: FC(F)(F)COC1C(OCCNC(CC2CC3C(N(CC3)CCCO)C(C2)C(=O)N)C)CCCC1.

UNSPSC 51262102 Silodosin is a Commodity code that nominally covers a specific pharmaceutical product, but recent state and local opportunities tagged under it show minimal alignment with the code's abstract scope. The two recent opportunities in the dataset — a Seminole County, Florida procurement for Naloxone and drug deactivation systems, and a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs — do not involve silodosin procurement. The code appears to see little relevant recent activity in state and local contracting, suggesting either sparse demand for this specific pharmaceutical under public procurement channels or systematic misclassification of opportunities in the issuing jurisdictions' cataloging systems.

The Seminole County opportunity (IFB 60459723LAS, response due July 26, 2023) sought 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive sealed bidding with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, requiring vendors to include shipping and delivery costs and comply with E-Verify and drug-free workplace certification. The Texas RFI (HHS0017013, posted April 3, 2026) represented early-stage market intelligence gathering on direct-to-manufacturer prescription fulfillment models rather than a formal solicitation. Neither opportunity involves the pharmaceutical product nominally described by the code, making this code a low-priority pursuit target unless your firm operates in pharmaceutical distribution channels and can clarify why these mistagged opportunities appear under the silodosin classification in procurement systems you are monitoring.